IRCT138801051778N1已完成未知
Evaluatoin of intravenous pamidronate effect on disease activity in patients with rheumatoid arthritis
Vice chancellery of research0 个研究点目标入组 37 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16 years 至 100 years（—）
- 性别
- All
入选标准
- •Rheumatoid arthritis patients who don’t have enough clinical and laboratory response to conventional disease modifying anti rheumatic drugs (DMARDs).
- •Exclusion criteria: patients who don’t want to have injection or had drug allergy or hypersensitivity, Drug reaction in the course of injection or after that, Lapse from study, Immigration or death.
排除标准
- 未提供
研究者
相似试验
招募中
2 期
Evaluation of intravenous pamidronate & oral alendronate on bone marrow density in ?patients with major and intermedia thalassemiaIRCT2017070420258N51Vice chancellor for research, Arak University of Medical Sciences40
已完成
2 期
Treatment of thalassemia-induced osteoporosis with pamidronateThalassemia.Beta thalassemiaD56.1IRCT20211008052698N1Oroumia University of Medical Sciences20
已完成
不适用
Study Into the Effect of Pamidronate for the Prevention of Heterotopic Ossification in High-Risk Patients: A Randomized Controlled TrialEstablished heterotopic ossificationMusculoskeletal DiseasesHeterotopic ossificationISRCTN01332857niversity Hospital of Basel (Switzerland)40
进行中（未招募）
不适用
Estudio comparativo de amiodarona intravenosa y procainamida intravenosa para tratamiento de la taquicardia regular de QRS ancho (probablemente ventricular ) con aceptable tolerancia clínica. - PROCAMIOTratamiento de la taquicardia regular de QRS ancho (probablemente ventricular) con aceptable tolerancia clínica.EUCTR2005-001505-25-ESFUNDACIÓN GREGORIO MARAÑÓ302
已完成
不适用
Therapeutic effect on disodium pamidronate administration to diffuse sclerosing mandible osteomyelitisdiffuse sclerosing osteomyelitisJPRN-UMIN000033725Department of Oral and Maxillofacial Surgery, Osaka Medical and Pharmaceutical University5